Researchers have developed and preliminarily tested a composite score that simultaneously assesses the severity of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with both ...

Standard care for CRSwNP consists of corticosteroids in the nose ... and 25% to 30% of them develop nasal polyps as a result. Sanofi and Regeneron have said that CRSwNP has been helping to ...

Learn the essential facts about fungal sinus infections, from recognizing early warning signs to understanding treatment ...

The CHMP opinion covers use of Dupixent with intranasal corticosteroids – the standard first-line treatment - in adults with the condition. In CRSwNP polyps obstruct the sinuses and nasal ...

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP ... provider can show you how to perform this process at home. Corticosteroid nasal spray is a medication you spray directly into your nose ...

Indication Systemic corticosteroids have been demonstrated ... [102] However, antihistamines are recommended for those patients with nasal polyps associated with atopy. Controversies See the ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

In the polypoid form of the disease, mucosal protrusions, or polyps, block the nasal and sinus cavities ... is treated with nasally administered corticosteroids and, in the case of the polypoid ...

PARIS, France I April 15, 2025 I Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for ...

(NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with ...